Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) EBIT Margin (2022 - 2025)

Historic EBIT Margin for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to 531.42%.

  • 60 Degrees Pharmaceuticals' EBIT Margin rose 10345800.0% to 531.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 837.78%, marking a year-over-year increase of 11035700.0%. This contributed to the annual value of 1598.97% for FY2024, which is 4338100.0% up from last year.
  • 60 Degrees Pharmaceuticals' EBIT Margin amounted to 531.42% in Q3 2025, which was up 10345800.0% from 1590.01% recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' EBIT Margin peaked at 1841.87% during Q4 2022, and registered a low of 5536.13% during Q1 2023.
  • Its 4-year average for EBIT Margin is 1534.21%, with a median of 1415.38% in 2023.
  • In the last 5 years, 60 Degrees Pharmaceuticals' EBIT Margin crashed by -33489900bps in 2023 and then skyrocketed by 42657600bps in 2024.
  • 60 Degrees Pharmaceuticals' EBIT Margin (Quarter) stood at 1841.87% in 2022, then crashed by -182bps to 1507.12% in 2023, then surged by 43bps to 854.61% in 2024, then soared by 38bps to 531.42% in 2025.
  • Its EBIT Margin stands at 531.42% for Q3 2025, versus 1590.01% for Q2 2025 and 1168.36% for Q1 2025.